QuorumCivic. Hidden in plain sight Get the app
Bill intelligence

Congress targets drug ads with tax deduction ban—but prices may rise

H.R. 3010 — No Handouts for Drug Advertisements Act · Filed by Gregory Murphy (R-NC) · 4 cosponsors · Introduced Apr 24, 2025 · Referred to committee

85%
Transparency
Typical bill: 85%
15/100
Hidden-provision risk
Typical bill: 15/100
Pharmaceutical Tax Policy

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

This bill amends the tax code to prohibit pharmaceutical companies from deducting the cost of direct-to-consumer drug advertising (TV commercials, social media ads, billboards, direct mail) as a business expense. The deduction ban applies to prescription drugs and compounded medications, but excludes ads in medical journals. Companies can no longer reduce their taxable income by the amount they spend on consumer-facing drug marketing.

Why we flagged it

The bill is a targeted tax provision that removes a specific deduction available to drug manufacturers. It is not a subsidy, immunity grant, or broad regulatory change—it is a narrowly scoped amendment to the Internal Revenue Code affecting one category of business expense.

What the text implies

  • The bill does not cap or regulate drug prices directly; it only removes a tax deduction. Pharmaceutical companies may offset the tax increase by raising drug prices, reducing advertising spend, or absorbing the cost—the outcome depends on market conditions and company strategy.
  • Direct-to-consumer drug advertising is a major driver of prescription volume and brand loyalty. Removing the tax deduction may reduce advertising spend, potentially lowering consumer demand for advertised drugs and shifting prescribing patterns toward generic or less-marketed alternatives.
  • The exception for journal advertising preserves deductions for ads in medical publications, which reach physicians rather than consumers. This creates a tax incentive favoring physician-directed marketing over consumer-directed marketing.
  • The bill applies to both branded prescription drugs and compounded medications. Compounding pharmacies, which are often smaller operations, may face proportionally higher tax burdens if they engage in direct-to-consumer advertising.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill reduces pharmaceutical marketing spend, which may lower drug prices or reduce manipulative advertising pressure on consumers—a public benefit. However, the mechanism is a tax increase on companies, which may be passed to consumers through higher drug prices, and the bill does not directly regulate drug pricing or advertising content, only the tax treatment of the expense.

Named in the bill

Internal Revenue Code of 1986, Federal Food, Drug, and Cosmetic Act, Pharmaceutical companies, Compounding pharmacies, Prescription drug manufacturers

Where it stands

4 cosponsors: 3 Democrats, 1 Republicans.

  • Apr 24, 2025 — Introduced · Congress.gov: “Introduced in House”
  • Apr 24, 2025 — Referred to House Committee on Ways and Means · Congress.gov: “Referred to the House Committee on Ways and Means”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 22 disclosure filings across 6 quarters, Jun 2025 to Sep 2026. Those filings disclosed $11,330,000 in lobbying spend. A filing names 21 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 74% of bills with at least one filing.

Gregory Murphy, the sponsor, reported $1,159,948 in PAC receipts in the 2026 cycle.

  • CVS Health (and Subsidiaries) — $9,550,000 on 4 filings
  • News Media Alliance — $1,080,000 on 2 filings
  • The Campaign for Sustainable Rx Pricing — $450,000 on 5 filings
  • Campaign for Sustainable Drug Pricing (csrxp) — $250,000 on 5 filings
  • Coalition for Healthcare Communications — $0 on 6 filings

Lobbying Disclosure Act filings through Oct 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.

How this was measured

Analysis — Quorum's AI read the bill text published by Congress.gov (2,434 characters) on Nov 21, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.

Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.

Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2025 to Sep 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.

As of — lobbying records through Oct 20, 2026 · page rendered 2026-11-22.

“Congress targets drug ads with tax deduction ban—but prices may rise” QuorumCivic. https://share.quorumcivic.app/bill/119/hr3010 Report an error

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the full bill text · 119th Congress · public record

The week in bills

One email, Sunday: what Congress passed, what it changed, and who paid.

One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.